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utive US FDA approvals of alirocumab in July and evolocumab in August
meant that they were in the spotlight at the European Society of Cardi-
ology and American Heart Association congresses—two of the largest
annual meetings of cardiologists in the world.
Thesemonoclonal antibodies (mAbs) bind to and inhibit the enzyme
proprotein convertase subtilisin/kexin type 9 (PCSK9). First identiﬁed in
2003 in patients with familial hypercholesterolemia, PCSK9's gain-of-
function mutations were associated with high levels of low-density li-
poprotein cholesterol (LDL-C) and early death due to coronary artery
disease (CAD). 2 years later, loss-of-function mutations in PCSK9 were
linked to low LDL-C levels and reduced CAD risk. These landmark stud-
ies have laid the groundwork for in-depth research into the underlying
mechanisms of PCSK9 inhibition and LDL-C lowering.
PCSK9 targets LDL receptors in hepatocytes for degradation, and
therefore inhibits the normal recycling of LDL receptor to the cell surface
required for metabolizing LDL-C. The resultant increased levels of circu-
lating LDL-C can lead to LDL-C buildup on the inner walls of blood ves-
sels (atherosclerosis)—a major risk factor for cardiovascular diseases.
The therapeutic effect of the PCSK9 mAbs alirocumab or evolocumab
is therefore to reduce LDL receptor degradation and lower LDL-C
amounts in the bloodstream.
For several decades, statins have been the cornerstone treatment for
high cholesterol. Yet fewer than half of the 74 million Americans with
hypercholesterolemia are being treated, and about 1 in 5 people on
maximally tolerated doses of statins cannot reach their LDL-C goal. Reg-
ulatory approval of the two new PCSK9 mAbs for familial hypercholes-
terolemia and those with clinical atherosclerotic disease, as an adjunct
to diet and maximally tolerated statin therapy, is therefore welcomed
news. It is anticipated that about 2–5 million Americans will be on
PCSK9 mAbs by the end of 2016.
PCSK9 inhibitors work synergistically with statins. Statin therapy re-
duces serum LDL-C levels by 30–40%, but the body responds by increas-
ing PCSK9 expression to compensate the drop in LDL-C. By reversing
statin-induced PCSK9upregulation, PCSK9mAbs can increase statin's ef-
fectiveness and decrease serum LDL-C levels by an additional up to 60%.
As with most therapeutic mAbs, alirocumab and evolocumab are
expensive—the estimated treatment cost is US$14,000 per year (com-
pared to a few hundred dollars a year for statin therapy), and treatment
is normally required for life (unlike mAbs in cancer therapy). mAbs also
require monthly injections, and despite a favorable short-term safety
proﬁle as observed in clinical trials, long-term side effects of very low
levels of LDL-C are unknown (e.g., neurocognitive problems). Clinical
outcomes (e.g., reduced risks of heart attack and stroke) also need
to be established, because regulatory approvals of alirocumab and
evolocumabhavebeenbased on a surrogatemarker (lower LDL-C levels).http://dx.doi.org/10.1016/j.ebiom.2015.12.006
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article underNevertheless, preliminary results from ongoing clinical trials of PCSK9
mAbs with long-term follow-up appear promising. Another PCSK9 mAb
(bococizumab) is also under development for hypercholesterolemia.
Although inhibition of PCSK9 bymAbs appears to be successful, other
promising approaches to inhibiting this pathway are also underway.
ALN-PCSSC is an investigational RNAi-based therapeutic that inhibits
PCSK9 synthesis. Early ﬁndings from a Phase 1 clinical trial have revealed
a durable effect on LDL-C reduction for 180 days after a single subcutane-
ous injection of ALN-PCSSC. Vaccination is another potential approach,
which also aims to address the short half-life of mAbs and can reduce
the necessity of monthly injections to annually by generating long-
lasting PCSK9-speciﬁc antibodies. Participants are being recruited to
Phase 1 clinical trials of two vaccine candidates (ATH04A and ATH06A),
following preclinical demonstration of a reduction of LDL-C levels in ex-
perimental animals lasting for up to 10 months post-vaccination.
Adnectin (BMS-962,476) is a small PCSK9-binding polypeptide al-
ternative to PCSK9mAbs, which has demonstrated good preclinical efﬁ-
cacy in mice and cynomolgus monkeys. The polypeptide has also been
tested for clinical safety in a single ascending-dose study in healthy sub-
jects and patients with elevated cholesterol on statins.
All of the above approaches require injection. For PCSK9 inhibitors to
become the next success after statins, an oral delivery formulation
would be advantageous, but itwould take arduous efforts to deliver pro-
teins and peptides in their intact forms through the gastrointestinal
tract. Statins are small-molecule inhibitors of the enzyme HMG-CoA re-
ductase, to be taken as oral pills. One might assume that a small-
molecule inhibitor for the enzyme PCSK9 would therefore be the most
straightforward approach. Given that the PCSK9 enzymatic structure is
rather ﬂat, designing a small-molecule inhibitor for it has been challeng-
ing so far.
Notwithstanding, there are a couple of small-molecule PCSK9
inhibitors in preclinical development, such as the oral PCSK9 antagonist
SX-PCK9. Another promising candidate is the new cholesteryl ester
transfer protein [CETP] inhibitor K-312 that also inhibits PCSK9 expres-
sion. K-312 has been shown to decrease PCSK9 expression in hepato-
cytes in a mechanism independent from CETP inhibition.
Undoubtedly there are remaining challenges in getting PCSK9 inhib-
itors from the research laboratory to the individuals who will beneﬁt
from the drugs. But with the two frontrunners alirocumab and
evolocumab approved, and a diverse pipeline of drug candidates, we
hope to see more PCSK9 inhibitors make it to the bedside with im-
proved efﬁcacy, ease of use, and lower cost in the near future.
EBioMedicinethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
